期刊
LIVER INTERNATIONAL
卷 40, 期 -, 页码 96-101出版社
WILEY
DOI: 10.1111/liv.14354
关键词
-
资金
- Conselho Nacional de Desenvolvimento Cientifico e Tecnologico de Pesquisa (CNPq)
- NIH [RO1 DK 105961]
- Fundacao Carlos Chagas de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ), Brazil
Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease in Western countries. At present the safest and most effective first-line therapy for the management of non-alcoholic steatohepatitis (NASH) is lifestyle modification with diet and exercise. However, long-term adherence to lifestyle modification is rare in the target population, leading to progression of liver disease and its complications such as cirrhosis and hepatocellular carcinoma. Thus, new drugs that focus mainly on the pathogenesis of NASH to target inflammation and fibrogenesis are under investigation. This mini-review summarizes the results of pivotal finalized phase 2 studies, and provide an outline of ongoing phase 2 and phase 3 studies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据